SCHEMBL3086465

SCHEMBL3086465

COc1ccc(-c2ccc([N+](=O)[O-])cc2)cn1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.59
PABPC1 P11940 2/20 0.59
KMT2A Q03164 2/20 0.59
POLB P06746 1/20 0.59
PDGFRB P09619 2/20 0.56
PDGFRA P16234 2/20 0.56
LMNA P02545 2/20 0.56
MAPT P10636 2/20 0.56
MKNK1 Q9BUB5 1/20 0.54
MKNK2 Q9HBH9 1/20 0.54
ERN1 O75460 2/20 0.53
KDM4E B2RXH2 1/20 0.51
ALDH1A1 P00352 1/20 0.51
GAA P10253 1/20 0.51
HSD17B1 P14061 1/20 0.49
HSD17B2 P37059 1/20 0.49
CYP2A6 P11509 2/20 0.49
APP P05067 1/20 0.46
HSPB1 P04792 2/20 0.44
KCNH2 Q12809 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1851173 0.86 KMT2A (0.70) MEN1PABPC1KMT2APOLBMAPT
SCHEMBL30850667 0.86 KMT2A (0.70) MEN1PABPC1KMT2APOLBMAPT
SCHEMBL16835850 0.86 KMT2A (0.59) MEN1PABPC1KMT2APOLBPDGFRB
SCHEMBL261553 0.81 MEN1 (0.57) MEN1PABPC1KMT2APOLBLMNA
SCHEMBL31174412 0.80 CYP2A6 (0.68) PDGFRBPDGFRAMKNK1MKNK2ERN1
SCHEMBL3754419 0.80 CYP2A6 (0.68) PDGFRBPDGFRAMKNK1MKNK2ERN1
SCHEMBL13166512 0.77 ERN1 (0.60) MEN1PABPC1KMT2APOLBPDGFRB
SCHEMBL3180698 0.77 MEN1 (0.56) MEN1PABPC1KMT2APOLBPDGFRB
SCHEMBL9098974 0.76 APP (0.57) MEN1KMT2APOLBPDGFRBPDGFRA
SCHEMBL9100117 0.76 APP (0.57) MEN1KMT2APOLBPDGFRBPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US disclosed
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US disclosed
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US disclosed
EP-2016057-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-01-21 EP disclosed
WO-2007123516-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-01 WO disclosed
WO-2007123516-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-01 WO disclosed
US-20060258666-A1 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2006-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258666-A1 c-fms kinase inhibitors FLT3, FES, FER MEN1 1293/4885PABPC1 4033/4885KMT2A 990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.